Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Context Therapeutics ( (CNTX) ).
On November 5, 2025, Context Therapeutics announced its third quarter 2025 financial results and provided updates on its clinical trials. The company is progressing with its CTIM-76 and CT-95 trials, showing promising safety profiles and preliminary anti-tumor activity in early phases. The company plans to continue dose escalation and expects to release further data in 2026, which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (CNTX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Context Therapeutics stock, see the CNTX Stock Forecast page.
Spark’s Take on CNTX Stock
According to Spark, TipRanks’ AI Analyst, CNTX is a Underperform.
Context Therapeutics has significant financial challenges, with no revenue and consistent losses, heavily weighing down its overall score. Technical analysis shows neutral market momentum, while valuation metrics highlight unprofitability. However, the recent initiation of a Phase 1 trial offers some hope for future growth. Collectively, these factors result in a low overall stock score, reflecting the company’s current financial instability and speculative potential.
To see Spark’s full report on CNTX stock, click here.
More about Context Therapeutics
Context Therapeutics Inc. operates in the biotechnology industry, focusing on developing T cell engagers (TCEs) for solid tumors. Their primary products include bispecific antibodies targeting tumor antigens such as Claudin 6, Mesothelin, and Nectin-4, which are overexpressed in various cancers. The company aims to address large market opportunities with limited competition.
Average Trading Volume: 292,303
Technical Sentiment Signal: Buy
Current Market Cap: $99.57M
For detailed information about CNTX stock, go to TipRanks’ Stock Analysis page.